Trinity Capital, a leading provider of diversified financial solutions to growth-stage companies, announced the commitment of $60 million in growth capital to Metabolon – a global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications.
Metabolon creates scientific, technological, and bioinformatics techniques to measure inputs from internal and external factors like health, disease, nutrition, microbiome, medication, and environmental exposure to answer scientific questions about health and disease. And Metabolon’s customizable metabolomics solutions support research in the biopharma, population health, consumer products, agriculture, wellness, academic, and government sectors across the research continuum.
This new growth funding round will enable Metabolon to expand its research and development efforts to further enhance its metabolomics platform. The funding will also support the company’s global expansion plans, including market penetration initiatives and strategic partnerships.
KEY QUOTES:
“We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector. By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research and we look forward to supporting the company’s ongoing growth and expansion in the industry.”
– Rob Lake, Senior Managing Director, Life Sciences at Trinity
“We are extremely pleased to announce this successful financing with Trinity, marking a significant milestone for Metabolon. This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon’s vision, capabilities, and market potential within the multiomics and metabolomics industry. As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space.”
– Rohan (Ro) Hastie Chief Executive Officer at Metabolon
